Advaxis, Inc. (NASDAQ:ADXS) was downgraded by investment analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research note issued on Tuesday.

A number of other brokerages have also commented on ADXS. Cantor Fitzgerald reiterated an “overweight” rating and issued a $19.00 price objective on shares of Advaxis in a research report on Wednesday, May 31st. HC Wainwright set a $23.00 price target on Advaxis and gave the company a “buy” rating in a research note on Wednesday, June 14th. Finally, BidaskClub downgraded Advaxis from a “hold” rating to a “sell” rating in a research note on Monday, July 31st. Two equities research analysts have rated the stock with a sell rating and three have issued a buy rating to the stock. Advaxis currently has a consensus rating of “Hold” and a consensus price target of $22.00.

Shares of Advaxis (NASDAQ ADXS) traded down 2.93% during midday trading on Tuesday, hitting $6.30. The stock had a trading volume of 359,138 shares. The stock has a 50 day moving average price of $6.60 and a 200-day moving average price of $7.96. The stock’s market capitalization is $254.91 million. Advaxis has a 52 week low of $5.70 and a 52 week high of $16.30.

TRADEMARK VIOLATION WARNING: “Advaxis, Inc. (ADXS) Downgraded to Strong Sell at ValuEngine” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/08/08/advaxis-inc-adxs-downgraded-to-strong-sell-at-valuengine.html.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. PNC Financial Services Group Inc. increased its position in Advaxis by 4.8% in the first quarter. PNC Financial Services Group Inc. now owns 22,000 shares of the biotechnology company’s stock worth $180,000 after buying an additional 1,000 shares during the period. FMR LLC increased its position in Advaxis by 4.5% in the first quarter. FMR LLC now owns 4,287,780 shares of the biotechnology company’s stock worth $35,031,000 after buying an additional 184,895 shares during the period. Vident Investment Advisory LLC increased its position in Advaxis by 20.0% in the first quarter. Vident Investment Advisory LLC now owns 108,941 shares of the biotechnology company’s stock worth $890,000 after buying an additional 18,156 shares during the period. American International Group Inc. increased its position in Advaxis by 7.6% in the first quarter. American International Group Inc. now owns 20,666 shares of the biotechnology company’s stock worth $169,000 after buying an additional 1,459 shares during the period. Finally, SG Americas Securities LLC increased its position in Advaxis by 2.9% in the first quarter. SG Americas Securities LLC now owns 49,333 shares of the biotechnology company’s stock worth $403,000 after buying an additional 1,398 shares during the period. 54.95% of the stock is currently owned by institutional investors.

Advaxis Company Profile

Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.